ArticleEuropean child & adolescent psychiatry2007
The EU-regulation on medicinal products for paediatric use: impacts on child and adolescent psychiatry and clinical research with minors.
Article in European child & adolescent psychiatry, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 29 citations in OpenAlex.
- In situ coating makes it easier for children to swallow and tolerate tablets and capsules.Acta paediatrica (Oslo, Norway : 1992) · 2015Trial
- Formulation Challenges and Strategies to Develop Pediatric Dosage Forms.Children (Basel, Switzerland) · 2022Review
- Low dissemination rates, non-transparency of trial premature cessation and late registration in child mental health: observational study of registered interventional trials.European child & adolescent psychiatry · 2020Observational
- [Off-label use in child and adolescent psychiatry. An ongoing ethical, medical and legal problem].Der Nervenarzt · 2009Review
- Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy.Child and adolescent psychiatry and mental health · 2009Article
- Recent developments and strategies in pediatric pharmacology research in the USA.Child and adolescent psychiatry and mental health · 2008Article
- The ethics of psychopharmacological research in legal minors.Child and adolescent psychiatry and mental health · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAt present the EU-regulation on medicinal products for paediatric use is in the final legislation phase. The Regulation will bring essential changes to the policy of research with minors, to funding and to regulations of drug development in Europe.
methodThe article analyses contents of the regulation and possible effects on research with and treatment of mentally ill minors.
resultsThe regulation seems to be a chance to improve pharmacological treatment for children and bring similar research conditions to Europe as they already exist in the US. Some terms of the regulation must be considered as critical due to vague definitions and ambiguously defined policies in some articles. The designated expert committee will be a powerful institution, but it remains to be seen whether this committee will act in the intended way. It is an existing and real danger that European child and adolescent psychiatry will be neglected by the new regulation, if there is no participation of scientists of this discipline in committees. The regulation makes it necessary for child and adolescent psychiatry to strengthen research in clinical trials and developmental psychopharmacology to get benefits from new legislation and improve health care for mentally ill minors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.